Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)

Revenue - Collaboration Agreement - The Astellas Collaboration Agreement (Details)	Jun. 30, 2024 USD ($)
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements	$ 154,393,000
Astellas Collaboration Agreement
Revenue
Aggregate transaction price of the contract modification	42,365,000
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details